29.76

4.83% 1.37

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$28.39

Aprire:

$28.74

Volume 24 ore:

2.45M

Relative Volume:

1.14

Capitalizzazione di mercato:

$3.07B

Reddito:

$164.01M

Utile/perdita netta:

$-65.04M

Rapporto P/E:

-43.32

EPS:

-0.687

Flusso di cassa netto:

$-383.84M

1 W Prestazione:

+11.25%

1M Prestazione:

+9.05%

6M Prestazione:

+7.87%

1 anno Prestazione:

+85.88%

Intervallo 1D:

$28.61

$30.50

Intervallo di 1 settimana:

$26.00

$30.50

Portata 52W:

$16.02

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (604)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

522

Cinguettio

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BEAM Beam Therapeutics Inc	29.76	2.93B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-20	Iniziato	Canaccord Genuity	Buy
2025-10-09	Iniziato	Jefferies	Buy
2025-03-28	Aggiornamento	BofA Securities	Neutral → Buy
2025-03-10	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-07-23	Iniziato	H.C. Wainwright	Buy
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

Aug 20, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat

Aug 20, 2026

Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet

Aug 20, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters

Aug 20, 2026

Aug 19, 2026

Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet

Aug 19, 2026

Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet

Aug 19, 2026

Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat

Aug 19, 2026

Aug 18, 2026

Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat

Aug 18, 2026

Aug 17, 2026

Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet

Aug 17, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 17, 2026

Aug 16, 2026

Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat

Aug 16, 2026

Aug 14, 2026

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan

Aug 13, 2026

Aug 11, 2026

Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat

Aug 11, 2026